SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 29, 2022 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of September 29, 2022 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of September 29, 2022 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
EMPLOYMENT AGREEMENTEmployment Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of September 29, 2022 by and between Solid Biosciences Inc. (the “Company”) and Bo Cumbo (the “Executive”) (together, the “Parties”).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Transition and Separation Agreement (the “Agreement”) is made as of September 29, 2022 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Ilan Ganot (the “Executive”) (together, the “Parties”).
FORM OF PARENT SUPPORT AGREEMENTForm of Parent Support Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of _______________, 2022, by and among AavantiBio, Inc., a Delaware corporation (the “Company”), Solid Biosciences Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
EXECUTIVE TRANSITION AND SEPARATION AGREEMENTExecutive Transition and Separation Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Transition and Separation Agreement (the “Agreement”) is made as of September 29, 2022 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Erin Powers Brennan (the “Executive”) (together, the “Parties”).
AGREEMENT AND PLAN OF MERGER by and among SOLID BIOSCIENCES INC., GREENLAND MERGER SUB LLC, AAVANTIBIO, INC., and, SOLELY IN HIS CAPACITY AS COMPANY EQUITYHOLDER REPRESENTATIVE, DOUG SWIRSKY Dated as of September 29, 2022Agreement and Plan of Merger • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into as of September 29, 2022, by and among: Solid Biosciences Inc., a Delaware corporation (the “Parent”); Greenland Merger Sub LLC, a Delaware limited liability company and a wholly owned subsidiary of the Parent treated as a disregarded entity for U.S. federal income Tax purposes (the “Transitory Subsidiary”); AavantiBio, Inc., a Delaware corporation (the “Company”); and solely in such Person’s capacity as the Company Equityholder Representative, Doug Swirsky (the “Company Equityholder Representative”).
FORM OF SUPPORT AND JOINDER AGREEMENTSupport and Joinder Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
This Support and Joinder Agreement (this “Agreement”) is made and entered into as of ________________, 2022, by and among AavantiBio, Inc., a Delaware corporation (the “Company”), Solid Biosciences Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
CONSULTING AGREEMENTConsulting Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consulting Agreement (together with Exhibit A, the “Agreement”), is by and between Erin Brennan (the “Special Advisor”), and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the “Company”), having an address at 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129.
CONSULTING AGREEMENTConsulting Agreement • September 30th, 2022 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consulting Agreement (together with Exhibit A, the “Agreement”), is by and between Ilan Ganot (the “Special Advisor”), and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the “Company”), having an address at 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129.
